Bhaskar Roy

Bhaskar Roy

Auto-generated profile, based on publicly available information

Bhaskar Roy

Department of Neurology, Yale School of Medicine, New Haven, CT

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
BRBhaskar Roy
Bhaskar Roy
RNRichard J. Nowak
Richard J. Nowak
RRRicardo Roda
Ricardo Roda
BKBabar Khokhar
Babar Khokhar
HPHuned S. Patwa
Huned S. Patwa
SRSeward B. Rutkove
Seward B. Rutkove

26 April 2022 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
AOAbeer H. Obaid
Abeer H. Obaid
CZChryssa Zografou
Chryssa Zografou
DVDouangsone D. Vadysirisack
Douangsone D. Vadysirisack
BMBailey Munro-Sheldon
Bailey Munro-Sheldon
MFMiriam L. Fichtner
Miriam L. Fichtner
KOKevin C. O'COnnor
Kevin C. O'COnnor
Background and Objectives Autoantibodies targeting the acetylcholine receptor (AChR), found in patients with myasthenia gravis (MG), mediate pathology through 3 mechanisms: complement-directed tissue damage, blocking of the acetylcholine binding site, and internalization of the AChR. Clinical assays, used to diagnose and monitor patients, measure only autoantibody binding. Consequently, they are limited in providing association with disease burden, understanding of mechanistic heterogeneity, and monitoring therapeutic response. The objective of this study was to develop a cell-based assay that measures AChR autoantibody–mediated complement membrane attack complex (MAC) formation. Methods An HEK293T cell line—modified using CRISPR/Cas9 genome editing to disrupt expression of the complement regulator genes (CD46, CD55, and CD59)—was used to measure AChR autoantibody–mediated MAC formation through flow cytometry. Results Serum samples (n = 155) from 96 clinically confirmed AChR MG patients, representing a wide range of disease burden and autoantibody titer, were tested along with 32 healthy donor (HD) samples. AChR autoantibodies were detected in 139 of the 155 (89.7%) MG samples through a cell-based assay. Of the 139 AChR-positive samples, autoantibody-mediated MAC formation was detected in 83 (59.7%), whereas MAC formation was undetectable in the HD group or AChR-positive samples with low autoantibody levels. MAC formation was positively associated with autoantibody binding in most patient samples; ratios (mean fluorescence intensity) of MAC formation to AChR autoantibody binding ranged between 0.27 and 48, with a median of 0.79 and an interquartile range of 0.43 (0.58–1.1). However, the distribution of ratios was asymmetric and included extreme values; 16 samples were beyond the 10–90 percentile, with high MAC to low AChR autoantibody binding ratio or the reverse. Correlation between MAC formation and clinical disease scores suggested a modest positive association (rho = 0.34, p = 0.0023), which included a subset of outliers that did not follow this pattern. MAC formation did not associate with exposure to immunotherapy, thymectomy, or MG subtypes defined by age-of-onset. Discussion A novel assay for evaluating AChR autoantibody–mediated complement activity was developed. A subset of patients that lacks association between MAC formation and autoantibody binding or disease burden was identified. The assay may provide a better understanding of the heterogeneous autoantibody molecular pathology and identify patients expected to benefit from complement inhibitor therapy.

30 October 2020 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
PDF file
QQQinwei Qiu
Qinwei Qiu
JWJingjing Wang
Jingjing Wang
YYYuhong Yan
Yuhong Yan
BRBhaskar Roy
Bhaskar Roy
YCYang Chen
Yang Chen
LHLijuan Han
Lijuan Han
The human gut microbiome is a reservoir for antibiotic resistance gene (ARG). Therefore, characterizing resistome distribution and potential disease markers can help manage antibiotics at the clinical level. While much population-level research has highlighted the strong effect of donor geographic origin on ARG prevalence in the human gut, little is known regarding the effects of other properties, such as age, sex, and disease. Here we employed 2,037 fecal metagenomes from 12 countries. By quantifying the known resistance genes for 24 types of antibiotics in each community, we showed that tetracycline, aminoglycoside, beta-lactam, macrolide-lincosamide-streptogramin (MLS), and vancomycin resistance genes were the dominant ARG types in the human gut. We then compared the ARG profiles of 1427 healthy individuals from the 2,037 samples and observed significant differences across countries. This was consistent with expectations that regional antibiotic usage and exposure in medical and food production contexts affect distribution. Although no specific uniform pattern of ARG was observed, a significant increase in resistance potential among multiple disease groups implied that the disease condition may be another source of ARG variance. In particular, the co-occurrence pattern of some enriched bacterial species and ARGs that were obtained in type 2 diabetes (T2D) and liver cirrhosis patients implied that some disease-associated species may be potential hosts of enriched ARGs, which could be potential biomarkers for the prediction and intervention of such diseases. Overall, our study identifies factors associated with the human gut resistome, including substantial effects of region and heterogeneous effects of disease status, and highlights the value of ARG analysis in disease research and clinical applications.

1 January 2021 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
SKSukanthi Kovvuru
Sukanthi Kovvuru
KNKrishna Nalleballe
Krishna Nalleballe
SOSanjeeva Reddy Onteddu
Sanjeeva Reddy Onteddu
RSRohan Sharma
Rohan Sharma
MJMadhu Jasti
Madhu Jasti
BRBhaskar Roy
Bhaskar Roy

1 January 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
ADAvash Das
Avash Das
SMSomnath Mahapatra
Somnath Mahapatra
DBDhrubajyoti Bandyopadhyay
Dhrubajyoti Bandyopadhyay
SSSantanu Samanta
Santanu Samanta
SCSandipan Chakraborty
Sandipan Chakraborty
BRBhaskar Roy
Bhaskar Roy

1 September 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
FKFatemeh Khani-Habibabadi
Fatemeh Khani-Habibabadi
BRBhaskar Roy
Bhaskar Roy
MPMinh C. Pham
Minh C. Pham
AOAbeer H. Obaid
Abeer H. Obaid
BFBeata Filipek
Beata Filipek
KOKevin C. O'COnnor
Kevin C. O'COnnor
Acetylcholine receptor (AChR) autoantibodies contribute to myasthenia gravis (MG) pathogenesis through 3 mechanisms: complement activation, receptor internalization, and acetylcholine (ACh) binding site blocking. Recently approved therapies target these autoantibodies by inhibiting the complement pathway or blocking the neonatal Fc receptor, reducing IgG autoantibody levels. However, these approaches have limitations: complement inhibitors do not address complement-independent mechanisms, and FcRn blockers only target IgG. Understanding how different pathogenic mechanisms, isotypes, and IgG subclasses are represented in the AChR autoantibody repertoire could lead to more precise application of therapeutics. To address this, we used advanced live cell-based assays to study autoantibody heterogeneity in longitudinally collected patient samples. Serum samples (N = 210) from 50 AChR IgG+ generalized MG patients collected longitudinally over 2 years were evaluated using a set of cell-based assays to measure complement activation, receptor internalization, ACh binding site blocking, and the frequency of the IgM and IgA isotypes and IgG subclasses. In cross-sectional samples, IgA and IgM autoantibodies co-occurred with IgG in 10% and 12% of patients, respectively. In addition, 4% of patients had all 3 isotypes (IgA, IgM, and IgG) present simultaneously. AChR-IgG1 was found in 67.4%, followed by IgG3 (21.7%) and IgG2 (17.4%). Complement was active in 84.8%, followed by AChR internalization (63%) and blocking (30.4%). Complement and AChR internalization were simultaneously active in 45.6%, complement and blocking were active in 10.8%, and all 3 pathomechanisms were active in 17.4%. Blocking alone was active in only 2.1%; AChR internalization alone was not found. Autoantibody binding capacity was associated with the magnitude of complement activation and AChR internalization. Temporal fluctuations of autoantibody binding capacity and the associated pathogenic mechanisms were observed. Pathogenic mechanisms were not associated with disease severity in cross-sectional analyses. However, longitudinally, disease severity measures followed a similar trend to the AChR autoantibody repertoire and mediated pathogenic mechanisms in some individuals, but not others. These findings highlight subsets of patients with MG with autoantibodies that can mediate pathogenic mechanisms or include isotypes that some therapeutics may not effectively target. Consequently, we suggest incorporating comprehensive autoantibody profiling into future MG clinical trials to further investigate potential associations with treatment outcomes.